Actively Recruiting
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Led by Mohsen Saidinejad · Updated on 2026-03-09
120
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
CONDITIONS
Official Title
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages 5-20 years
- Diagnosed sickle cell disease including HbSS, HbSC, HbSBetaThal Plus or Zero
- Presenting with vaso-occlusive episode pain requiring intravenous pain medication
- First dose of analgesic medication given before study approach
- Primary language is English or Spanish
- Adult or parent/legal guardian able and willing to provide informed consent; assent provided by ages 7 to 17 when possible
You will not qualify if you...
- Sickle cell trait only
- Primary language other than English or Spanish
- Pain caused by reasons other than vaso-occlusive episode
- Not requiring intravenous pain treatment
- No analgesic given before study approach for any reason
- Oxygen saturation less than 90% on room air
- History of adverse reaction to ketamine
- Active or uncontrolled hypertension (systolic over 140 mmHg or diastolic over 90 mmHg)
- Significant or uncontrolled cardiovascular, liver, kidney, or thyroid disease
- Evidence of increased intracranial or elevated intraocular pressure
- Acute mania or bipolar disorder with mania, hallucinations, or paranoia
- Pregnant or potentially pregnant patients
- Elevated liver enzymes indicating liver dysfunction
- Patients appearing intoxicated
- Patients who are wards of the state or prisoners
- Patients not competent to provide consent or assent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Harbor UCLA Medical Center
Torrance, California, United States, 90509
Actively Recruiting
Research Team
C
Cynthia Luo, MD
CONTACT
M
Mohsen Saidinejad, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here